Blog

Enveda Biosciences has raised $311 million to drive AI-based drug development, focusing on nature-derived treatments for skin issues and weight management.

Vijay Pande discusses his shift from a16z to VZVC, emphasizing smaller bets, the engineering mindset in biotech, and the importance of open datasets for AI in medicine.

The use of AI to create new viruses raises potential benefits for combating antibiotic resistance, but it also triggers urgent ethical and regulatory concerns.

Anthropic's $400M acquisition of Coefficient Bio marks a pivotal moment, blending AI and biotechnology for future healthcare innovations.

ByteDance's Protenix-v1 aims to rival AlphaFold3 in biomolecular structure prediction. This open-source model could democratize access and accelerate biotech innovations.